rss
Br J Ophthalmol 2008;92:210-212 doi:10.1136/bjo.2007.127902
  • Original Article

Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration

  1. S V Goverdhan,
  2. J Lochhead
  1. Ophthalmology Department, St Mary’s Hospital, Newport, Isle of Wight, UK
  1. Mr J Lochhead, Consultant Ophthalmologist, Department of Ophthalmology, St Mary’s Hospital, Newport PO30 5TG, Isle of Wight, UK; jonathan.lochhead{at}iow.nhs.uk
  • Accepted 7 October 2007
  • Published Online First 26 October 2007

Abstract

Objective: To report the occurrence of submacular haemorrhages following intravitreal bevacizumab for occult choroidal neovascularisation (CNV) in age-related macular degeneration (AMD).

Methods: Retrospective chart review of 53 patients with occult CNV who had received intravitreal bevacizumab 1.25 mg. Analysis was done in three groups based on mean CNV lesion size: <10 mm2 (n = 17), ≥10 to <15 mm2 (n = 17) and ≥15 mm2 (n = 18). ETDRS derived acuity, incidence of fresh macular haemorrhages and haemorrhage size (pre-existing or fresh) were documented and analysed.

Results: The median injection number was 1.0 (range: 1 to 3) with a minimum follow-up of 6 months (range: 4 to 12 months). The mean presenting size of occult lesions was 13.4 mm2 (range: 3.0 to 30.3 mm2). Submacular fresh haemorrhages were seen in the absence of pre-existing haemorrhage in four out of 10 patients in the ≥15 mm2 CNV size group (40%) but none in the remaining groups with CNV sizes <15 mm2 (OR = 20.1, p = 0.01, 95% CI = 0.99 to 409.3). These haemorrhages developed at a median of 14 days.

Conclusions: Submacular haemorrhages seem to be a significant adverse event following intravitreal bevacizumab in large occult choroidal neovascularisation and may affect visual outcomes. Prospective studies are required to establish the optimal dose of bevacizumab for larger lesion sizes or to identify the most appropriate anti-VEGF agent in large occult CNV with fibrovascular and serous PED lesions.

Footnotes

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2007.127902v1
    2. 92/2/210 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.